BRCR Medical Center | Plantation, FL
Status and phase
Conditions
Treatments
About
This is a multicenter, open-label, single-arm Phase II study to evaluate anti-tumor efficacy and safety of NT-I7 in combination with atezolizumab in subjects with PD-L1-expressing (TPS ≥ 1%), metastatic (Stage IV) or locally advanced squamous or non-squamous NSCLC who have not received prior systemic therapy in the metastatic or locally advanced setting. Eligible subjects must have measurable disease according to RECIST 1.1. This Phase II study will enroll up to 83 subjects.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
83 participants in 1 patient group
Loading...
Central trial contact
Byung Ha Lee, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal